May 7, 2023

New drug slows Alzheimer’s

Posted by in categories: biotech/medical, life extension, neuroscience

Drug company Eli Lilly reports that donanemab can slow the pace of Alzheimer’s disease by 35%, following a Phase 3 study in human patients.

Brain scans of Alzheimer’s patients with treatment (A and B) and placebo ©, showing clearance of amyloid plaques. Credit: Eli Lilly.

In recent years, Alzheimer’s has become an increasingly major public health issue. The prevalence of this disease – a progressive neurological disorder that affects memory, thinking, and behaviour – is being driven by aging populations, changes in lifestyle factors, and improvements in diagnostic techniques.

Leave a reply